| Followers | 30 |
| Posts | 3322 |
| Boards Moderated | 0 |
| Alias Born | 08/21/2015 |
Monday, June 14, 2021 12:31:13 PM
“SP was approaching 2.30 *after* the FDA letter dropped it to $2. Then the 13d reared their head and here we sit in the 1.80s
That’s a .50 drop due solely to the uncertainty of who the 13d are and what they claim to be planning.”
Entirely false.
The SP closed at $2.04 on May 17th, the day the FDA letter was released, a decrease of .78 or 27% from the opening SP of $2.82. The stock closed at $2 on the 18th and $1.81 on the 19th, 24 hours after the previous day’s CC.
The stock opened at $2.21 and closed at $2.12 on May 24th, the day the 13d 8k was released AFTER HOURS. The stock closed on the 25th at 2.01, a drop of .11 or 5% from $2.12. It closed at $1.99 the following day and $1.90 after that, only to rebound to a closing of $2.05, $2.06 and $2.11 in the 3 subsequent trading days.
So, please explain in detail how the 13d dropped the price .50 from $2.30 when the SP wasn’t near $2.30 when the 8k was released (it was $2.12) nor did the stock drop to $1.80 shortly after it was released (lowest was $1.90).
The stock fluctuations mostly entirely due to the FDA letter and the subsequent, abysmal CC.
That’s a .50 drop due solely to the uncertainty of who the 13d are and what they claim to be planning.”
Entirely false.
The SP closed at $2.04 on May 17th, the day the FDA letter was released, a decrease of .78 or 27% from the opening SP of $2.82. The stock closed at $2 on the 18th and $1.81 on the 19th, 24 hours after the previous day’s CC.
The stock opened at $2.21 and closed at $2.12 on May 24th, the day the 13d 8k was released AFTER HOURS. The stock closed on the 25th at 2.01, a drop of .11 or 5% from $2.12. It closed at $1.99 the following day and $1.90 after that, only to rebound to a closing of $2.05, $2.06 and $2.11 in the 3 subsequent trading days.
So, please explain in detail how the 13d dropped the price .50 from $2.30 when the SP wasn’t near $2.30 when the 8k was released (it was $2.12) nor did the stock drop to $1.80 shortly after it was released (lowest was $1.90).
The stock fluctuations mostly entirely due to the FDA letter and the subsequent, abysmal CC.
Recent CYDY News
- CytoDyn Announces First Patient Dosed in Expanded Access Program for Leronlimab in Triple-Negative Breast Cancer • GlobeNewswire Inc. • 04/27/2026 12:30:00 PM
- CytoDyn to Host Investor Webcast • GlobeNewswire Inc. • 04/23/2026 12:30:00 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 04/22/2026 09:21:50 PM
- CytoDyn Presents New Leronlimab Data in Metastatic Colorectal Cancer at AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/22/2026 12:30:00 PM
- CytoDyn Completes Enrollment in Phase 2 Metastatic Colorectal Cancer Study • GlobeNewswire Inc. • 04/21/2026 08:10:00 PM
- CytoDyn Presents New Leronlimab Data in Metastatic Triple-Negative Breast Cancer at AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/20/2026 12:30:00 PM
- CytoDyn to Present at the AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/14/2026 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 04/08/2026 09:15:18 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/08/2026 12:30:28 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/25/2026 09:16:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:24:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:23:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:22:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:21:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:57 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/24/2026 09:15:24 PM
- CytoDyn Presents at AACR Special Conference in Cancer Research: Brain Cancer • GlobeNewswire Inc. • 03/24/2026 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/09/2026 09:15:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/05/2026 01:35:02 PM
- CytoDyn Closes $17.5 Million Financing to Fund Continued Development of Leronlimab • GlobeNewswire Inc. • 03/05/2026 01:30:00 PM
- CytoDyn Presents Novel CCR5 Inhibition Mechanisms and Long-Term Survival Signals for Leronlimab in Metastatic Breast Cancer at AACR Immuno-Oncology Conference • GlobeNewswire Inc. • 02/20/2026 01:30:00 PM
- CytoDyn Announces Funding and Initiation of Expanded Access Program for Patients with Triple-negative Breast Cancer • GlobeNewswire Inc. • 01/27/2026 01:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 01/09/2026 10:15:22 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 01/09/2026 01:30:45 PM
